Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 873-881     DOI: 10.31083/j.rcm2203093
Special Issue: State-of-the-Art Cardiovascular Medicine in Asia 2021
Systematic Review Previous articles | Next articles
Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis
Wanting Wang1, Zhaoqiang Feng2, Jinghui Bai1, *()
1General Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, 110042 Shenyang, Liaoning, China
2Hepatobiliary Pancreatic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, 110042 Shenyang, Liaoning, China
Download:  PDF(1446KB)  ( 185 ) Full text   ( 22 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Evaluation of the effects of alirocumab on cardiovascular (CV) events, CV mortality and all-cause mortality. Data search was carried out using the Cochrane Library, PubMed, Web of Science and Embase. The search time is up to November 18, 2020. All randomized clinical trials (AEs) comparing alirocumab with placebo were searched. Meta-analysis was performed by Review Manager version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark), and the heterogeneity between studies was tested by Cochrane's Q test and measured with I2 statistics. A total of 13 randomized controlled trials with 24,815 participants were included. Alirocumab usage can considerably lower the incidence of CV events when compared to the control group (risk ratio(RR) 0.89, 95% confidence interval(CI) 0.83–0.95). No significant difference in CV mortality between the two groups was observed (RR 0.87, 95% CI 0.74–1.04). Treatment with alirocumab has been associated with a major decrease in all-cause mortality compared to placebo (RR 0.80, 95% CI 0.66–0.96). The incidence of serious adverse events (AEs) was similar in the two groups (RR 0.94, 95% CI 0.90–0.99). Alirocumab can reduce CV events and all-cause mortality. The AEs were mild and tolerable.
Key words:  Alirocumab      CV events      All-cause mortality      Meta-analysis     
Submitted:  06 July 2021      Revised:  26 July 2021      Accepted:  13 August 2021      Published:  24 September 2021     
*Corresponding Author(s):  Jinghui Bai     E-mail:  baijinghuizlyy2@163.com

Cite this article: 

Wanting Wang, Zhaoqiang Feng, Jinghui Bai. Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis. Reviews in Cardiovascular Medicine, 2021, 22(3): 873-881.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203093     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/873

[1] Andrea Messori, Laura Bartoli, Elisa Ferracane, Sabrina Trippoli. Medical therapy, radiofrequency ablation or cryoballoon ablation as first-line treatment for paroxysmal atrial fibrillation: interpreting efficacy through restricted mean survival time and network meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 557-561.
[2] Yao-Yao Han, Zheng-Xiang Li, Rong Duan. Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 167-174.
[3] Feng Shi, Yuchen He, Shiyue Wang, Fuqiang Jia, Chao Ji, Jian Zhang, Xun Liu, Yanshuo Han. Endovascular and open surgical repair of abdominal aortic aneurysms: A comparative analysis of western and chinese studies[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 75-92.
[4] Guicheng Liang, Beizhu Xu, Shirong Wang, Chengxuan Li, Guoqiang Zhong. Imaging with intracardiac echocardiography compared to transesophageal echocardiography during left atrial appendage occlusion[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 93-101.
[5] En Chen, Wei Cai, Danqing Hu, Lianglong Chen. Effect of remote ischemic preconditioning in patients with STEMI during primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 103-112.
[6] Wan Chin Hsieh, Anas Aboud, Brandon M. chael Henry, Mohamed Omara, Jaroslav Lindner, Jan Pirk. Serum albumin in patients undergoing transcatheter aortic valve replacement: A meta-analysis[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 161-169.
[7] Yifan Luo, Lixiang Ren, Mingyan Jiang, Yang Chu. Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 91-98.
[8] Bu-Chun Zhang, Cheng Wang, Zhi-Wen Zhou, Yan-Feng Ma, Wen-Hua Li, Dong-Ye Li. Coronary Plaque Characteristics Affect No-Reflow During Primary Percutaneous Coronary Intervention: A Pooled Analysis of 14 Observational Studies Using Intravascular Ultrasound[J]. Reviews in Cardiovascular Medicine, 2015, 16(3): 200-213.
[9] Gao Wei, Ren Yaqi, Wang Ningfu, Hou Xuwei. N-terminal Prohormone B-type Natriuretic Peptide and Cardiovascular Risk in Stable Coronary Artery Disease: A Meta-analysis of Nine Prospective Studies[J]. Reviews in Cardiovascular Medicine, 2013, 14(2-4): 92-98.
No Suggested Reading articles found!